Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 10:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–16 of 16 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Cancer-Associated Weight Loss Clear all
Completed No phase listed Observational Accepts healthy volunteers

Cancer-Associated Muscle Atrophy and Weakness: An Investigation of Etiology

NCT03012139
View directory record Official record
Conditions
Metastatic Cancer, Cachexia; Cancer
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
35 Years to 80 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 21, 2020 · Synced Oct 22, 2026, 10:17 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) - 1

NCT03743051
View directory record Official record
Conditions
Cachexia; Cancer, Non Small Cell Lung Cancer
Interventions
Anamorelin Hydrochloride, Placebo Oral Tablet
Drug
Lead sponsor
Helsinn Healthcare SA
Industry
Eligibility
18 Years and older
Enrollment
318 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
24
States / cities
Tucson, Arizona • Little Rock, Arkansas • Riverside, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 22, 2026, 10:17 PM EDT
Completed Phase 3 Interventional

Creatine in Treating Patients With Cancer-Associated Weight Loss

NCT00081250
View directory record Official record
Conditions
Anorexia, Cachexia, Unspecified Adult Solid Tumor, Protocol Specific, Weight Changes
Interventions
creatine monohydrate, placebo
Dietary Supplement · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2017
U.S. locations
220
States / cities
Mobile, Alabama • Scottsdale, Arizona • Aurora, Colorado + 139 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2020 · Synced Oct 22, 2026, 10:17 PM EDT
Completed Phase 1 Interventional

Evaluating the Combined Intervention of Nutritional Supplementation (Remune) and Exercise in Patients With Cancer Cachexia

NCT04131426
View directory record Official record
Conditions
Cachexia; Cancer, Weight Loss, Lung Cancer, Gastrointestinal Cancer
Interventions
Remune, EXCAP©®
Drug · Other
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Aug 15, 2023 · Synced Oct 22, 2026, 10:17 PM EDT
Not yet recruiting Phase 1 Interventional

A Study to Learn About the Study Medicine Called Ponsegromab in Adults With Lung Cancer-Associated Significant Body Weight Loss

NCT07663630
View directory record Official record
Conditions
Non-small Cell Lung Cancer (NSCLC), Cachexia
Interventions
ponsegromab, placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
6
States / cities
Decatur, Illinois • O'Fallon, Illinois • Garland, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 22, 2026, 10:17 PM EDT
Recruiting Phase 2Phase 3 Interventional

Visugromab in Cachexia International Trial

NCT07112196
View directory record Official record
Conditions
Cancer-associated Cachexia
Interventions
Visugromab (CTL-002), Placebo
Drug
Lead sponsor
CatalYm GmbH
Industry
Eligibility
18 Years and older
Enrollment
518 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
10
States / cities
Norwich, Connecticut • Clermont, Florida • Orange City, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 22, 2026, 10:17 PM EDT
Recruiting Phase 2 Interventional

Olanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced Esophagogastric, Hepatopancreaticobiliary, Colorectal or Lung Cancer

NCT05705492
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Advanced Biliary Tract Carcinoma, Advanced Esophageal Carcinoma, Metastatic Esophageal Carcinoma, Locally Advanced Colorectal Carcinoma, Locally Advanced Esophageal Carcinoma, Locally Advanced Gastric Carcinoma, Metastatic Colorectal Carcinoma (mCRC), Advanced Lung Carcinoma, Locally Advanced Hepatocellular Carcinoma
Interventions
Olanzapine, Placebo Administration, Questionnaire Administration
Drug · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 22, 2026, 10:17 PM EDT
Terminated Phase 3 Interventional Results available

Treatment of Cancer-associated Anorexia Using Megestrol Acetate Concentrated Suspension

NCT00637806
View directory record Official record
Conditions
Anorexia, Cachexia, Weight Loss
Interventions
Megestrol acetate concentrated suspension 110 mg/mL, Megestrol acetate concentrated suspension 60 mg/mL, Placebo
Drug
Lead sponsor
Par Pharmaceutical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
4
States / cities
Anaheim, California • Flat Rock, North Carolina • High Point, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated May 2, 2016 · Synced Oct 22, 2026, 10:17 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Tocilizumab Combined With First-Line Chemo-Immunotherapy in Metastatic Non-Small Cell Lung Cancer

NCT07889232
View directory record Official record
Conditions
Metastatic Non-Small Cell Lung Cancer, Cancer-Associated Weight Loss, Elevated Inflammatory Markers
Interventions
Tocilizumab, Pembrolizumab, Platinum-Doublet Chemotherapy
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
4
States / cities
Indianapolis, Indiana • Ann Arbor, Michigan • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 22, 2026, 10:17 PM EDT
Terminated No phase listed Observational

Pilot Project for Cardiopulmonary and Functional Evaluation in Patients With Pancreatic Cancer Associated Cachexia

NCT02580422
View directory record Official record
Conditions
Cachexia, Pancreatic Cancer
Interventions
Not listed
Lead sponsor
Indiana University
Other
Eligibility
Not listed
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 23, 2018 · Synced Oct 22, 2026, 10:17 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Low Fat Versus Protein Sparing Diet for Weight Loss & Impact on Biomarkers Associated With Breast Cancer Risk

NCT01559194
View directory record Official record
Conditions
Breast Cancer, Weight Loss
Interventions
Low Fat Diet plus exercise, Low Carbohydrate diet + Exercise
Behavioral
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
30 Years and older · Female only
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 14, 2014 · Synced Oct 22, 2026, 10:17 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) - 2

NCT03743064
View directory record Official record
Conditions
Cachexia; Cancer, Non Small Cell Lung Cancer
Interventions
anamorelin HCl, Placebo Oral Tablet
Drug
Lead sponsor
Helsinn Healthcare SA
Industry
Eligibility
18 Years and older
Enrollment
318 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
19
States / cities
Tucson, Arizona • Anaheim, California • Bakersfield, California + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 22, 2026, 10:17 PM EDT
Terminated Phase 3 Interventional Results available

Treatment of Cancer-anorexia Using Megestrol Acetate Concentrated Suspension in Lung or Pancreatic Cancer Patients

NCT00637728
View directory record Official record
Conditions
Anorexia, Cachexia, Weight Loss
Interventions
Megestrol acetate concentrated suspension 110 mg/mL, Placebo
Drug
Lead sponsor
Par Pharmaceutical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
3
States / cities
Miami, Florida • Cumberland, Maryland • Mt. Pleasant, South Carolina
Source: ClinicalTrials.gov public record
Updated Jun 23, 2016 · Synced Oct 22, 2026, 10:17 PM EDT
Terminated Phase 2 Interventional Results available

Haelan and Nutrition in Cancer Patients

NCT00558558
View directory record Official record
Conditions
Anorexia, Weight Loss, Cachexia
Interventions
Haelan
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 13, 2016 · Synced Oct 22, 2026, 10:17 PM EDT
Completed Phase 3 Interventional

Etanercept in Treating Cancer-Related Cachexia and Anorexia in Patients With Advanced Cancer

NCT00046904
View directory record Official record
Conditions
Anorexia, Cachexia, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
etanercept
Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
19
States / cities
Mobile, Alabama • Scottsdale, Arizona • Jacksonville, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated May 5, 2011 · Synced Oct 22, 2026, 10:17 PM EDT
Completed Phase 3 Interventional

Comparison of Nutritional Supplements in Preventing Weight Loss in Patients With Cancer

NCT00053053
View directory record Official record
Conditions
Cachexia, Lymphoma, Lymphoproliferative Disorder, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
Juven, Non-Juven Supplement
Dietary Supplement
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
17 Years to 120 Years
Enrollment
472 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
230
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 181 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2016 · Synced Oct 22, 2026, 10:17 PM EDT